Inozyme Retained Earnings from 2010 to 2025

INZY Stock

USD 0.97 0.04 4.27%

Inozyme Pharma Retained Earnings yearly trend continues to be fairly stable with very little volatility. Retained Earnings are likely to outpace its year average in 2025. Retained Earnings is the cumulative amount of net income that Inozyme Pharma retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2019-12-31

Previous Quarter

-360.9 M

Current Value

-388 M

Quarterly Volatility

106.3 M

Covid

Check Inozyme Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inozyme Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 1.6 M, Interest Income of 8 M or Depreciation And Amortization of 541.8 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.16. Inozyme financial statements analysis is a perfect complement when working with Inozyme Pharma Valuation or Volatility modules.

Check out the analysis of Inozyme Pharma Correlation against competitors.

For more information on how to buy Inozyme Stock please use our How to Invest in Inozyme Pharma guide.

Latest Inozyme Pharma's Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Inozyme Pharma over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Inozyme Pharma's Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inozyme Pharma's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (387.95 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Inozyme Retained Earnings Regression Statistics

	Arithmetic Mean	(104,061,331)
	Geometric Mean	43,263,999
	Coefficient Of Variation	(129.94)
	Mean Deviation	110,574,330
	Median	(14,928,000)
	Standard Deviation	135,222,441
	Sample Variance	18285.1T
	Range	373M
	R-Value	(0.84)
	Mean Square Error	5632.4T
	R-Squared	0.71
	Significance	0.000039
	Slope	(23,974,408)
	Total Sum of Squares	274276.6T

Inozyme Retained Earnings History

	2025	-368.6 M
	2024	-388 M
	2023	-285.9 M
	2022	-214.8 M
	2021	-147.7 M
	2020	-91.1 M
	2019	-34.7 M

Other Fundumenentals of Inozyme Pharma

Retained Earnings Total Equity

Inozyme Pharma Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Capital Surpluse	Total Liab	Deferred Long Term Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Long Term Debt	Long Term Debt Total	Short Long Term Debt
Total Assets		0.97	0.94	-0.04	-0.78	0.75	0.73	1.0	0.91	-0.56	0.81	0.99	1.0	0.99	0.78	0.81	0.75	0.37	0.67	-0.31	-0.31
Total Stockholder Equity	0.97		0.95	-0.17	-0.69	0.83	0.58	0.96	0.87	-0.74	0.76	0.98	0.96	0.96	0.66	0.86	0.71	0.28	0.5	-0.24	-0.24
Net Tangible Assets	0.94	0.95		-0.14	-0.77	0.9	0.66	0.95	0.92	-0.66	0.84	0.97	0.93	0.89	0.78	0.88	0.78	0.44	0.53	-0.32	-0.32
Net Debt	-0.04	-0.17	-0.14		-0.39	-0.33	0.32	0.0	0.16	0.43	0.04	-0.05	0.02	-0.03	0.38	-0.03	0.48	0.34	0.49	-0.3	-0.3
Retained Earnings	-0.78	-0.69	-0.77	-0.39		-0.64	-0.94	-0.8	-0.95	0.25	-0.77	-0.78	-0.8	-0.73	-0.92	-0.67	-0.86	-0.83	-0.84	0.74	0.74
Accounts Payable	0.75	0.83	0.9	-0.33	-0.64		0.5	0.75	0.82	-0.78	0.76	0.79	0.72	0.67	0.55	0.85	0.62	0.48	0.22	-0.38	-0.38
Net Receivables	0.73	0.58	0.66	0.32	-0.94	0.5		0.74	0.84	-0.06	0.69	0.7	0.75	0.69	0.87	0.51	0.68	0.83	0.92	-0.78	-0.78
Short Term Investments	1.0	0.96	0.95	0.0	-0.8	0.75	0.74		0.92	-0.54	0.84	0.99	1.0	0.98	0.81	0.83	0.78	0.4	0.69	-0.33	-0.33
Capital Surpluse	0.91	0.87	0.92	0.16	-0.95	0.82	0.84	0.92		-0.53	0.84	0.92	0.91	0.86	0.86	0.83	0.87	0.68	0.7	-0.6	-0.6
Total Liab	-0.56	-0.74	-0.66	0.43	0.25	-0.78	-0.06	-0.54	-0.53		-0.35	-0.62	-0.52	-0.55	-0.11	-0.73	-0.34	-0.06	0.12	0.09	0.09
Deferred Long Term Liab	0.81	0.76	0.84	0.04	-0.77	0.76	0.69	0.84	0.84	-0.35		0.79	0.81	0.75	0.76	0.79	0.78	0.48	0.53	-0.34	-0.34
Net Invested Capital	0.99	0.98	0.97	-0.05	-0.78	0.79	0.7	0.99	0.92	-0.62	0.79		0.99	0.98	0.78	0.84	0.77	0.38	0.63	-0.3	-0.3
Total Current Assets	1.0	0.96	0.93	0.02	-0.8	0.72	0.75	1.0	0.91	-0.52	0.81	0.99		0.99	0.81	0.79	0.77	0.38	0.71	-0.32	-0.32
Net Working Capital	0.99	0.96	0.89	-0.03	-0.73	0.67	0.69	0.98	0.86	-0.55	0.75	0.98	0.99		0.73	0.77	0.71	0.29	0.67	-0.26	-0.26
Common Stock	0.78	0.66	0.78	0.38	-0.92	0.55	0.87	0.81	0.86	-0.11	0.76	0.78	0.81	0.73		0.57	0.87	0.64	0.86	-0.47	-0.47
Property Plant Equipment	0.81	0.86	0.88	-0.03	-0.67	0.85	0.51	0.83	0.83	-0.73	0.79	0.84	0.79	0.77	0.57		0.78	0.39	0.38	-0.3	-0.3
Current Deferred Revenue	0.75	0.71	0.78	0.48	-0.86	0.62	0.68	0.78	0.87	-0.34	0.78	0.77	0.77	0.71	0.87	0.78		0.53	0.65	-0.37	-0.37
Short Term Debt	0.37	0.28	0.44	0.34	-0.83	0.48	0.83	0.4	0.68	-0.06	0.48	0.38	0.38	0.29	0.64	0.39	0.53		0.63	-0.95	-0.95
Long Term Debt	0.67	0.5	0.53	0.49	-0.84	0.22	0.92	0.69	0.7	0.12	0.53	0.63	0.71	0.67	0.86	0.38	0.65	0.63		-0.57	-0.57
Long Term Debt Total	-0.31	-0.24	-0.32	-0.3	0.74	-0.38	-0.78	-0.33	-0.6	0.09	-0.34	-0.3	-0.32	-0.26	-0.47	-0.3	-0.37	-0.95	-0.57		1.0
Short Long Term Debt	-0.31	-0.24	-0.32	-0.3	0.74	-0.38	-0.78	-0.33	-0.6	0.09	-0.34	-0.3	-0.32	-0.26	-0.47	-0.3	-0.37	-0.95	-0.57	1.0

Click cells to compare fundamentals

About Inozyme Pharma Financial Statements

Inozyme Pharma investors use historical fundamental indicators, such as Inozyme Pharma's Retained Earnings, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inozyme Pharma. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Retained Earnings	-388 M	-368.6 M
Retained Earnings Total Equity	-193.3 M	-202.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Inozyme Stock Analysis

When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC